Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Review · May 08, 2021

Association Between Cardiovascular Adverse Events and Intravitreal Anti-VEGF Drugs

JAMA Ophthalmology


Additional Info

JAMA Ophthalmology
Cardiovascular Adverse Events With Intravitreal Anti-Vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
JAMA Ophthalmol 2021 Apr 15;[EPub Ahead of Print], N Ngo Ntjam, M Thulliez, G Paintaud, F Salvo, D Angoulvant, PJ Pisella, T Bejan-Angoulvant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading